

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	N/A

*FHK- Florida Healthy Kids

Varubi (rolapitant hydrochloride) oral capsules

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Varubi (rolapitant hydrochloride) oral capsules	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Varubi (rolapitant hydrochloride) capsules may be approved when the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual is using for prevention of delayed nausea and vomiting associated with initial and repeat courses of one of the following emetogenic cancer chemotherapy: :
 - A. Highly emetogenic chemotherapy (label, NCCN 1); **OR**
 - B. Moderately emetogenic chemotherapy (NCCN 1);**AND**
- III. Individual is using in combination with dexamethasone and a 5-HT3 receptor antagonist.

Requests for Varubi (rolapitant hydrochloride) capsules may not be approved for the following:

- I. Individual is taking a CYP2D6 substrate with a narrow therapeutic index (such as, thioridazine and pimozide).

NOTE:

Varubi (rolapitant hydrochloride) capsules dosing:

Prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

- I. 180 mg (2 – 90 mg capsules) administered approximately 1-2 hours prior to the start of chemotherapy.
- II. Administer in combination with dexamethasone (20mg dexamethasone on day 1) and a 5-HT3 receptor antagonist.
- III. Administer prior to the initiation of each chemotherapy cycle but at no less than 2 week intervals.

PAGE 1 of 2 03/02/2018

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	N/A

*FHK- Florida Healthy Kids

State Specific Mandates		
State mandate	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.